Elucid raises $55M Series D to advance its AI software for cardiovascular CT analysis.
Key Details
- 1Boston-based Elucid closed an oversubscribed $55 million Series D round.
- 2Funding included participation from a major, unnamed, publicly traded medtech firm.
- 3Elucid has raised over $185 million to date.
- 4Its AI software assists physicians in analyzing CT scans for signs of cardiovascular disease.
- 5The funding will support clinical platform expansion, FFR-CT development (under FDA review), and continued R&D.
- 6Elucid now has four large, publicly traded strategic investors.
Why It Matters
Significant investment underscores the continued momentum and competition in AI-driven cardiovascular imaging. The funding supports further product development and regulatory progress, potentially impacting diagnostic accuracy and patient care in radiology.
Source
Radiology Business
Related News
•Radiology Business
UC Irvine Implements AI to Find Lung Cancer Screening Candidates
UC Irvine's radiology department developed an NLP tool to identify patients eligible for lung cancer screening from EHR notes.
•Radiology Business
Webinar to Showcase Successful AI Automation in Radiology Workflows
A webinar will provide insights from imaging leaders on expanding and optimizing AI-driven automation in radiology clinical workflows.
•Radiology Business
A Practical Guide to Evaluating Radiology AI Solutions
Experts propose a three-step approach for radiologists to assess and select AI imaging solutions.